New oral medication shows promise for more quickly treating MRSA skin infections, researchers find

Share this article:

A new oral antibiotic may effectively treat MRSA-related skin infections more quickly than the only oral drug currently approved, according to research published Wednesday in the Journal of the American Medical Association.

Researchers led by Philippe Prokocimer, M.D., the chief medical officer at Trius Therapeutics Inc., compared the effectiveness of tedizolid phosphate with linezolid. Linezolid is the only oral medication currently approved to treat certain skin infections caused by methicillin-resistant Staphylococcus Aureus (MRSA).

The acute bacterial skin and skin structure infections (SSSIs) caused by MRSA can be fatal, and there have been outbreaks of linezolid-resistant strains of MRSA, the researchers noted.

In a 667-person trial carried out in North America, Latin America and Europe, participants received either a daily dose of tedizolid phosphate for six days or a dose of linezolid every 12 hours for 10 days.

Based on clinical outcomes, the researchers determined the newer drug is “clinically noninferior” to linezolid.

Nursing homes experience a high rate of community-associated MRSA, according to a study in the March issue of Infection Control and Hospital Epidemiology.

Share this article:
close

Next Article in News

More in News

White House creates new national strategy on antibiotics

White House creates new national strategy on antibiotics

The Obama administration has unveiled a national strategy to combat antibiotic-resistant bacteria. It includes an executive order to direct the federal government to "reduce the emergence and spread of antibiotic-resistant ...

Medicaid provider agreement remains legitimate during bankruptcy proceedings, judge rules

Medicaid must continue to make payments to a Florida nursing home undergoing bankruptcy proceedings, a federal judge rule recently.

Legislator pushes for more HCBS services for Medicaid beneficiaries

Medicaid beneficiaries would have an opportunity to receive more care in a home or community-based setting if a House of Representatives bill passes.